Game changer for hepatitis C diagnosis – NCI Division of Cancer Prevention
NCI Division of Cancer Prevention shared a post on LinkedIn:
“Cancer prevention can sometimes mean treating a chronic disease or infection that, left untreated, can lead to cancer, as can happen with a chronic hepatitis C virus (HCV) infection. Getting tested for HCV is important because an HCV infection is curable.
In June, the FDA granted U.S. marketing authorization for the first rapid hepatitis C virus test that can be used in patient care settings and deliver results in about one hour.
The new technology – validated through a collaboration between RADx Tech at The National Institutes of Health, FDA and Centers for Disease Control and Prevention – could help patients with positive tests begin treatment right away, rather than the current approach, which requires lengthy laboratory processing.
Read more about this game changer for hepatitis C diagnosis.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023